Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, Robert E. Smith
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286299186